Phase 1/2a Study of ANPD001 in Parkinson Disease
NCT:NCT06344026 · ENROLLING_BY_INVITATION
广告
NCT编号NCT06344026
状态ENROLLING_BY_INVITATION
开始日期2024-01-23
完成时间2030-04-30
SponsorAspen Neuroscience (INDUSTRY)
First posted
Last updated
简要摘要
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.
官方来源
在 ClinicalTrials.gov 上查看 →数据来自 ClinicalTrials.gov API。有关最新状态,请参阅官方记录。